Navigation Links
Lorus initiates development program exploring novel route of administration for LOR-2040
Date:4/22/2008

TORONTO, April 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.

The new development program will examine direct (intravesical) administration of LOR-2040 into the bladder as a treatment for superficial or non-invasive bladder cancer. Formal toxicology evaluation, which is currently in progress, will be used to determine the appropriate human dose and dose schedule for LOR-2040 with this route of administration.

Results of these studies will be used in support of an Investigational New Drug (IND) application for the use of LOR-2040 in the treatment of bladder cancer. Lorus intends to submit the IND during Q3, 2008, following successful completion of the toxicology program.

LOR-2040, formerly known as GTI-2040, has shown potent antiproliferative activity and target downregulation in bladder cancer in preclinical studies. LOR-2040 is currently being investigated in several phase I and phase II clinical trials in a broad range of cancer indications, both alone and in combination with a number of standard cancer therapies. In clinical trials, LOR-2040 has demonstrated a high safety profile when administered intravenously, which is the current route of administration for this drug.

In the U.S. more than 60,000 new cases of bladder cancer are diagnosed each year, which accounts for approximately 13,000 deaths annually. At initial diagnosis, up to 90% of subjects with bladder cancers have superficial disease that is confined to the inner layers of tissue in the urinary bladder. Systemic chemotherapy is considered less effective than the intravesical (instilled in the bladder) agents in treating lo
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. SemBioSys initiates toxicology study for safflower-produced insulin
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
10. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & ... stem cell technology start-up company Asymmetrex to share the first report on ... a new biomarker for counting adult tissue stem cells. , With a name like ...
(Date:8/25/2015)... Aug. 25, 2015 Human Longevity, Inc. (HLI), the ... has joined the company as Chief Operating Officer. Winham, ... operations and technical experience, will report directly to HLI,s CEO, ... this new role as COO, Winham will be responsible for ... well as all facility operations. HLI currently has three locations ...
(Date:8/25/2015)... Aug. 25, 2015 Doximity, the leading ... physicians, today launched its second annual Residency ... the next generation of doctors research and compare ... percent of all senior medical students used Doximity ... as new physicians. The new Residency Navigator brings ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2Doximity Releases 2015-2016 Residency Navigator 2Doximity Releases 2015-2016 Residency Navigator 3
... Inc. (Amex:,ADL), headquartered in Tustin, California, with ... its wholly owned subsidiary Jade,Pharmaceutical Inc., is ... development, manufacture and marketing of proprietary pharmaceutical,and ... detailed report on the,Company, its prospects in ...
... Orifice Surgery, AUSTIN, Texas, Oct. 8 ... devices for minimally invasive,surgical procedures conducted through natural ... Series A financing from PTV Sciences, H.I.G.,Ventures, and ... to complete product development and conduct human clinical ...
... Preliminary results from a,clinical study comparing INVEGA(TM) (paliperidone) ... in patients with,recent, acute exacerbation of schizophrenia will ... the 20th Annual U.S. Psychiatric and Mental Health,Congress, ... FL. The poster, entitled "A Comparative Analysis ...
Cached Biology Technology:ValueRich Report on AMDL/China Available on Web Site 2Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing. 2Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing. 3Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 2Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 3Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 4
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... system, every protein made in the cell has a specific ... proteins to their appropriate target. Researchers at Boston University ... images of these channels as they open to allow proteins ... made. These findings are published as a Letter in ...
... apps, cameras, and mobile internet to navigate strange cities in ... in line, and upload their videos directly to social media ... high-tech savvy can save a well-loved device from dying when ... same basic ailment that plagues solar power plants and wind ...
... A drug currently on the market to treat leukemia reversed ... findings by medical researchers with the University of Alberta. ... team,s discovery in the peer-reviewed journal, PLOS ONE . ... can also play an important role in the development of ...
Cached Biology News:Researchers capture images of open channel that moves proteins across cell membranes 2Futuristic copper foam batteries get more bang for the buck 2Futuristic copper foam batteries get more bang for the buck 3UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3